Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The main question this study is trying to answer is whether lumateperone, an FDA-approved
antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain
and elevated levels of sugar and bad cholesterol.
Participants will be randomly assigned to either take lumateperone (Caplyta) or a placebo for
12 weeks, in addition to their regularly prescribed clozapine. During their participation,
patients will answer questions about their psychiatric and daily functioning, have blood
drawn, and have their body composition analyzed (similar to stepping on a scale).